在耐药癌细胞和细菌中对药物流量具有潜在双重抑制活性的化合物的鉴定:系统审查议定书
Elina Beleva1,2, Antonia Diukendjieva1, Ilza Pajeva1
1QSAR and Molecular Modelling, Institute of Biophysics and Biomedical Engineering, Bulgarian Academy of Sciences, Sofia, Bulgaria.
JMIR research protocols
|June 5, 2025
概括
本系统性审查确定了可以在细菌和癌细胞中逆转多药耐药性 (MDR) 的化合物. 这些发现将有助于设计双流量抑制剂,以有效打击MDR.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 细菌和癌细胞中的多药耐药性 (MDR) 通常由药物排泄介导.
- 开发排泄抑制剂是克服MDR的关键策略.
- 识别具有针对细菌和癌症MDR双重活性的化合物是非常可取的.
研究的目的:
- 系统地审查可以逆转抗菌和癌症MDR的化合物.
- 确定影响排水相互作用的结构和生物参数.
- 为了为双流量抑制剂的合理药物设计提供基础.
主要方法:
- 按照PRISMA-P指南进行系统审查.
- 在PubMed和Scopus数据库中进行了搜索 (2012年1月 - 2024年9月).
- 包括在体外研究中,评估在使用排泄抑制剂治疗后对抗微生物药物和化疗药物的敏感性变化.
主要成果:
- 预测概述潜在的双重作用化学敏感剂.
- 结果将突出能够逆转抗微生物和癌症MDR的化合物.
- 数据将以叙事形式合成,并以表格和图形格式呈现.
结论:
- 排泄抑制是一种有效的策略,可以在细菌和癌症中对抗MDR.
- 这次审查将强调阻力机制的重叠.
- 结构化数据将促进新型双排泄抑制剂的合理设计.
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combined Effects of Drugs: Synergism
4.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.9K


